New approaches for measuring coagulation
|
|
- Bryce Young
- 6 years ago
- Views:
Transcription
1 Haemophilia (2006), 12, (Suppl. 3), New approaches for measuring coagulation T. W. BARROWCLIFFE, M. CATTANEO,* G. M. PODDA,* P. BUCCIARELLI, F. LUSSANA,* A. LECCHI, C. H. TOH, à H. C. HEMKER, S. BÉGUIN, J. INGERSLEV and B. SØRENSEN *Unità di Ematologia e Trombosi, Ospedale San Paolo, Università di Milano, Italy; A. Bianchi Bonomi Hemophilia and Thrombosis Center IRCCS Ospedale Maggiore, Milano, Italy; à Royal Liverpool University Hospital, Liverpool, UK; Cardiovascular Research Institute Maastricht (CARIM), Universiteit van Maastricht, Maastricht, The Netherlands; and University Hospital Skejby, Aarhus, Denmark Summary. Although specific assays of coagulation factors are essential for diagnostic purposes they only give partial information about an individual s haemostatic state. This can be better assessed by various global tests, and recent developments and evaluations of five such tests are described in this symposium: the PFA-100; waveform analysis; thrombin generation; overall haemostasis potential; thrombelastography. Each test has advantages in various applications, but the thrombin generation test and waveform analysis have been found most useful in haemophilia, whilst the PFA-100 is helpful in von Willebrand s disease. Keywords: coagulation, global tests, bleeding disorders Introduction As knowledge of the coagulation system developed in the 1950s onwards, specific assays were devised for most of the main clotting factors, and these largely replaced most of the non-specific global tests such as thrombin generation and thrombelastography. However, in recent years there has been a recognition that specific assays may not be sufficiently informative to assess the patient s overall haemostatic state and that more global tests may contribute useful additional information. Another reason for the revival of global assays is the development of technical innovations and more sophisticated methods of analysis, which have improved their reliability and reproducibility and led to more widespread use. In this symposium, the clinical utility of three such global assays is described. Dr Marco Cattaneo assesses the PFA-100 as an in vitro substitute for the bleeding time; Dr H. Coenraad Hemker describes the use of thrombin potential, as determined by the thrombin generation test, in haemophilia; Dr Cheng Hock Toh discusses the application of waveform analysis in bleeding disorders. Finally, Dr Jorgen Ingerslev compares the use of waveform, thrombin Correspondence: Dr Trevor W. Barrowcliffe, 35 Oakhurst Avenue, East Barnet, Herts EN4 8DL, UK. Tel.: ; twbarrowcliffe@yahoo.co.uk generation and traditional bioassays in haemophilia patients. The PFA-100Ò versus the bleeding time in the diagnosis of bleeding disorders We compared the performance of PFA-100Ò closure time (CT) and skin bleeding time (BT) in the diagnostic work-up of 128 consecutive patients referred to our centre to be screened for bleeding disorders. The correlation with the severity of the bleeding symptoms and the sensitivity of BT and PFA-100 CT for known defects of primary haemostasis were evaluated. All patients underwent (i) a careful medical interview and were assigned a Ôbleeding scoreõ, based on the number, type, frequency and severity of bleeding symptoms; (ii) firstline screening [prothrombin time, activated partial thromboplastin time (APTT), PFA-100 CT both the collagen-adp (C-ADP) and the collagen-epinephrine (C-EPI), cartridges and BT]. The search for von Willebrand s disease (VWD), platelet function disorders (PFD), clotting factor defects and abnormalities of fibrinolysis was performed according to the results of the first-line screening tests and the severity and type of bleeding history. Seven (6%) patients had type 1 VWD, 12 (9%) PFD, 29 (23%) defects of clotting factors, 18 (14%) prolongations of the APTT as a result of the abnormalities that are not associated with bleeding (factor XII deficiency and 76 Journal compilation Ó 2006 Blackwell Publishing Ltd
2 NEW APPROACHES FOR MEASURING COAGULATION 77 lupus anticoagulant), while in 63 (49%) all tests gave normal results. The sensitivity of PFA-100 for VWD was 86% (both cartridges), for PFD 75% (C-EPI) and 8% (C-ADP). The sensitivity of BT for VWD was 29%, for PFD 33%. After dividing the patient population into four quartiles of distribution, according to the severity of the bleeding score, only the CT of the PFA-100 CT of C-EPI showed a progressive and significant prolongation from the first to the fourth quartile (P ¼ 0.04). In conclusion, (i) CT of the PFA-100 C-EPI was significantly associated with the severity of the bleeding history; (ii) PFA-100 CT showed a better sensitivity than BT for VWD and PFD; (iii) at variance with the BT, PFA-100 could help discriminate between VWD (prolongation of CT of both cartridges) and PFD (prolongation of CT of the C-EPI cartridge only). The application of waveform analysis in coagulation Waveform analysis is the optical profile of clot formation on simple assays of coagulation, such as the activated partial thromboplastin time (aptt) [1]. Optical profiles can be characterized using a set of parameters describing onset and completion of coagulation, magnitude of signal change, rate of coagulation and other properties. Work from our group has shown that this can be atypical in patients with haemostatic dysfunction [2]. The biphasic waveform (BPW) was initially described when a decrease in plasma light transmittance prior to clot formation on the MDA 180Ò automated coagulation analyzer (biomérieux, Marcy, France) was shown to correlate with disseminated intravascular coagulation (DIC) in critically ill patients [3]. In contrast to the normal sigmoidal waveform pattern that is characterized by an initial 100% light transmittance phase prior to clot formation, patients with a biphasic pattern had an immediate, progressive fall in light transmittance that occurred even in the preclotting phase [4]. The magnitude of this BPW often varied with sequential samples taken from individual patients and appeared early in samples from patients who were later diagnosed with DIC by more conventional criteria [5]. The utility of this for the forewarning of DIC, the diagnosis of sepsis and the risk of mortality have been validated by others both in the intensive care and in the emergency room setting [6 8]. In contrast to the significance of the initial slope (slope 1), work by others has also demonstrated the utility of the second derivative of the waveform. The group at Nara University has shown that this aspect of aptt waveform analysis can be utilized in the assessment of factor VIII (FVIII) levels below 1.0 IU dl )1. Whereas conventional one-stage clotting assays are insufficiently sensitive at this level, Shima et al. [9] have shown that FVIII levels of 0.2 IU dl )1 can be measured reproducibly and that such accurate discrimination has phenotypic relevance and clinical significance. Furthermore, this can be utilized to monitor the effectiveness of FVIII infusions in haemophilia A patients with high responding inhibitors. In the presence of type 1 inhibitors quantified at 6 14 BU ml )1, 0.9 IU dl )1 FVIII could be detected 24 h after FVIII infusion [10]. This suggests that FVIII infusion may be continued with clinical benefit in some haemophiliacs with high responding inhibitors and that the haemostatic response can be monitored accurately and efficiently by waveform analysis. For those that do not respond to FVIII and require recombinant factor VIIa, waveform analysis can also indicate dosedependent improvements in clot formation [11]. Thrombin potential in haemophilia Haemophilia is a deficiency of factor VIII (FVIII) or IX (FIX) that leads to a defect in the thrombingenerating system of the blood. Although in haemophiliacs the deficient factor limits the haemostatic function, it is not its sole determinant. Its residual activity remains dependent upon the ensemble of clotting factors, platelets and the vessel wall. This is best illustrated by the observation that substitution with factor VIIa (FVIIa) instead of the lacking FVIII or FIX can restore haemostasis. In addition, the common clinical observation that haemophiliacs with identical residual levels of the missing factor can show large variations in bleeding tendency stresses this point. It therefore seems logical to try and measure the affected function rather than the missing factor, at least that part of the function, which is accessible because it is located in the blood, i.e. thrombin generation. Indeed, it can be shown that thrombin generation in haemophiliac blood is dependent on other factors than the deficient one. It is, for example, proportional to the prothrombin level and inversely proportional to the antithrombin level and augmented by inhibition of the activated protein C system. The most important practical reason for measuring thrombin generation in haemophiliacs is in fact its sensitivity to FVIII bypassing therapy with FVIIa-containing preparations. A typical thrombin generation curve (Fig. 1) shows a lag time, a steep rising slope and a slower declining Journal compilation Ó 2006 Blackwell Publishing Ltd Haemophilia (2006), 12, (Suppl. 3), 76 81
3 78 T. W. BARROWCLIFFE et al. Thrombin (nm) Time (min) Fig. 1. Effect of factor VIII infusion on thrombin generation in a haemophilic patient. 50 IU kg )1 was given to a haemophilic patient. Upper fat line: normal plasma; lower fat line: patient before injection; thin lines: patient after injection. From top to bottom at the following times after injection: 15 min, 1, 3, 5, 24, 48, 30, 60 h. The thrombin generation curves are obtained with the CAT method using 2 pm tissue factor as a trigger. slope. Important parameters are the peak of thrombin activity attained and the area under the curve or endogenous thrombin potential (ETP). The importance of the latter parameter derives from the fact that it indicates how much substrate thrombin can convert during its lifetime in plasma. This parameter can only be found if the entire course of thrombin generation is recorded. The ETP and the peak value together determine the gradient of thrombin, which forms around a local trigger and hence the extent of the recruitment of all haemostatic mechanisms (on platelets and vessel wall) that are triggered by thrombin. It also determines the amount of thrombin-activatable fibrinolysis inhibitor (TAFI) formed and thus the resistance of the haemostatic plug to fibrinolysis. The fibrinolytic character of much haemophiliac bleeding suggests a direct link between late bleeding tendency and ETP via this mechanism. This may explain the fibrinolysis often observed in thrombelastography when thrombin generation is low. The thrombin generation curve can be obtained by either subsampling or conversion of a slow chromogenic or fluorogenic substrate. In the last few years, we developed calibrated automated thrombinography, a method that can record the concentration of thrombin in clotting platelet-poor plasma (PPP) or platelet-rich plasma (PRP) continuously in up to 24 samples. It is based on the conversion of a slowreacting small fluorogenic substrate that does not interfere with the normal mechanism of prothrombin conversion. It slows down thrombin inactivation by a precisely known percentage (50%), which depends upon the binding constant of the substrate and the amount added. When this is corrected for, the resulting curves superimpose with those obtained by subsampling under identical conditions. With this method, the restoration of thrombin generation in haemophiliacs by infusion of FVIII preparations (Fig. 1) or by preparations containing activated factor VII is readily seen. An approximate impression of thrombin generation can also be obtained by surrogate methods, i.e. methods that do not render thrombin concentration (in nm) as a function of time. Measuring the first derivative of substrate conversion without proper calibration gives curves that to the non-initiated looks deceivingly like a thrombogram but that gives a distorted view and introduces important errors. The first derivative being a function of both thrombin concentration and substrate concentration, variation in the latter needs to be corrected for by continuous calibration. If not, low thrombin generation, as in haemophilia, is overestimated because more fluorogenic substrate is available towards the end of the reaction than in the normal thrombin generation. Other surrogate methods are based on the conversion of fibrinogen into fibrin, measuring either its turbidity or its tensile strength. Through mathematical manipulation, curves can be obtained, which look like thrombin generation (TG) curves but are not. Because fibrinogen is converted into fibrin long before all prothrombin is converted into thrombin, essentially only the lag time of the thrombelastogram is comparable to one of the parameters of the actual thrombin generation curve. After clotting occurs, the signal results from the changing properties of the clot rather than from the amount of thrombin present. The method has the advantage that it can be carried out in whole blood and that fibrinolysis is readily observed. The latter, via TAFI, may be a secondary effect of a low ETP (see above). Surrogate methods have the additional disadvantage that the signals are influenced by variables outside the thrombin-generating system, such as fibrinogen content, and the Ca ++ -dependent interaction of very low-density lipoproteins and C-reactive protein. In contrast to the classical view, it becomes more and more obvious that platelets are not just responsible for that phase of haemostasis that occurs before thrombin is formed. Recent experiments show clearly that thrombin starts to form within seconds after a lesion occurs. Platelets influence the amount and the effect of thrombin formed in at least three ways: by forming an aggregate from which the formed thrombin cannot be washed away, by providing the required procoagulant phospholipids and by releasing factor V. Thrombin generation in Haemophilia (2006), 12, (Suppl. 3), Journal compilation Ó 2006 Blackwell Publishing Ltd
4 NEW APPROACHES FOR MEASURING COAGULATION 79 platelet-rich plasma, therefore, is one step nearer again to complete physiological function testing than TG in PPP. This is especially important in von Willebrand s disease where impaired thrombin generation can be demonstrated, that is not, or only partly, due to the lack of FVIII but must be attributed to impaired platelet activation via the fibrin von Willebrand factor (VWF) GPIb platelet activation axis [12]. By comparison of the thrombin generation test in PRP to that in PPP with added phospholipids, this phenomenon allows to differentiate between the effect on thrombin generation of FVIII and of VWF. Experiences in comparison of waveform, thrombin generation test and bioassay in haemophilia patients Historically, laboratory practises adopted in the management of haemophilia in recent times have been based on the experiments conducted in the early 1950s when the activated partial thromboplastin time (APTT) method was first devised [13]. Today, a prolonged APTT test result found in a male person with an abnormal tendency to bleeding should always raise suspicion of haemophilia, and the relevant investigation will include a bioassay recording the level of factor VIII and/or factor IX (FIX) based on the APTT methods. Should the patient suffer from haemophilia, APTT assays are also employed to monitor treatment. Thus, common laboratory routines around haemophilia are closely linked with the earliest small signal of fibrin formation. However, one must be aware that the APTT method only records the beginning of the overall clotting process, leaving >95% of the reaction untold. For this reason, methods were developed and published providing more detail of the entire course of the clotting process in haemophilia as early as 55 years ago. In principle, two avenues were followed: one type of assay recorded the thrombin activity generated during the coagulation process [14], while the other assay illustrated the formation of fibrin during clotting [15]. In the original versions, these methods were quite crude and imprecise and were not well suited for routine use and therefore were not generally adopted in clinical work. Thrombin generation methods Recent progress has refined these assays to a large extent, and the thrombin generation principle has been used more generally in haemostasis research [16,17]. As thrombin formation occurring during plasma coagulation is quite explosive by nature, slow-reacting substrates have been developed and introduced. For practical reasons, in particular when the thrombin generation test is used in the study of plasma with platelets, thrombin-induced peptide hydrolysis in a chromogenic reaction has been superseded by fluorogenic substrates [18]. In order to study continuous thrombin generation in plasma, either fibrinogen must be removed or its polymerization into fibrin must be inhibited. The continuous curve of thrombin generation is usually differentiated and derived parameters such as the lag time, the peak value and the area under the curve are employed in the interpretation of the signal. Most commonly, the activator is tissue factor in small amounts, but a variety of concentrations of tissue factor have been used, making direct comparisons quite difficult. A major clinical and laboratory hallmark of haemophilic plasma clotting the prolonged initiation phase seems to be lost if too much tissue factor is used for activation [19]. Alternatively, for the study in haemophilia A, the use of activated FIX as an activator has been more successful in this regard [20]. Fibrin formation methods The systems developed for recording fibrin formation, as assessed by the change in the viscoelastic properties of blood or plasma during coagulation, had to come quite some way until velocity characteristics were introduced to substitute for the classical Ôbrandy-glassÕ shape signature. Two systems are available today and quite comparable in performance: the thrombelastograph and the rotating thrombelastometer. Compared with Hartert s original model, the new equipments employ single-use reaction cells and the raw continuous signal may be converted into velocity by differentiation. With the viscoelastic recorders, the optimal activator for study in haemophilia is tissue factor in low concentrations at 0.35 pm or less [21]. These assays appear to mirror the haemophilic bleeding phenotype quite well, as the initiation of clotting is severely prolonged in severe haemophilia, and the fibrin formation signal lacks acceleration and is weakly represented [22]. Overall haemostasis potential In addition, a slightly different system has been communicated, in which fibrin formation dynamics in plasma is recorded by photometry following activation with a small amount of thrombin. This method denoted the overall haemostasis; haemo- Journal compilation Ó 2006 Blackwell Publishing Ltd Haemophilia (2006), 12, (Suppl. 3), 76 81
5 80 T. W. BARROWCLIFFE et al. static potential also has the convenience of measuring the fibrinolytic resistance of the clot. The most recent report demonstrates the feasibility of the method in hypocoagulable states such as haemophilia and other single factor deficiencies [23]. A study was recently reported comparing thrombin generation with fibrin formation in whole blood showing a quite convincing correlation between the two principles of recording whole blood coagulation in a continuous manner. As fibrin formation is the consequence of thrombin generation, this finding is by no means surprising [24]. Conclusions The PFA-100 would appear to be useful in the diagnosis of different types of von Willebrand s disease (VWD) and in distinguishing VWD from platelet function. As well as showing a better correlation with the various bleeding disorders, the PFA-100 has the clear advantage over the bleeding time of practical convenience. Analysis of the waveform of the clotting process can be carried out in a number of ways with appropriate instrumentation. The biphasic waveform is atypical in disseminated intravascular coagulation and has been found useful in diagnosing this coagulation abnormality. In haemophilia, analysis of the second derivative has allowed quantitative measurements at Factor VIII (FVIII) levels below I IU dl )1 and has proved useful in monitoring the treatment of inhibitor patients. The thrombin generation test can be used to monitor treatment in haemophilia and gives more information than factor assays, as it takes into account non-fviii influences on clotting, such as thrombin-activatable fibrinolysis inhibitor. However, the concentration of tissue factor is critical for the application of thrombin generation test (TGT) in haemophilia, and an alternative activator that has been used successfully is Factor IXa. Two other tests that may be of clinical benefit are thrombelastography and the overall haemostasis potential, although these have not been studied as intensively in haemophilia as TGT and waveform analysis. References 1 Braun PJ, Givens TB, Stead AG et al. Properties of optical data from activated partial thromboplastin time and prothrombin time assays. Thromb Haemost 1997; 3: Downey C, Kazmi R, Toh CH. Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation. Br J Haematol 1997; 98: Downey C, Kazmi R, Toh CH. Early identification and prognostic implications in disseminated intravascular coagulation through transmittance waveform analysis. Thromb Haemost 1998; 80: Toh CH, Samis J, Downey C et al. The biphasic transmittance waveform in the aptt coagulation assay is due to the formation of a Ca ++ -induced complex of C-reactive protein with very low density lipoprotein and is a novel marker of impending disseminated intravascular coagulation. Blood 2002; 100: Toh CH, Ticknor LO, Downey C, Giles AR, Paton R, Wenstone R. Early identification of sepsis and mortality risks through simple, rapid clot-waveform analysis. Intensive Care Med 2003; 29: Dempfle CE, Lorenz S, Smolinski M et al. Utility of activated partial thromboplastin time waveform analysis for identification of sepsis and overt disseminated intravascular coagulation in patients admitted to a surgical intensive care unit. Crit Care Med 2004; 32: Smith EY, Charles LA, Van Cott EM. Biphasic activated partial thromboplastin time waveform and adverse events in non-intensive care unit patients. Am J Clin Pathol 2004; 121: Fernandes B, Giles AR. An abnormal activated partial thromboplastin time clotting waveform is associated with high mortality and a procoagulant state. Lab Hematol 2003; 9: Shima M, Matsumoto T, Fukuda K et al. The utility of activated partial thromboplastin time clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity. Thromb Haemost 2002; 87: Kasuda S, Tanaka I, Shima M et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004; 10: Sima M. Understanding the hemostatic effects of recombinant factor VII a by clot waveform analysis. Semin Hematol 2004; 41(Suppl. 1): Béguin S, Kumar R, Keularts I, Seligsohn U, Coller BS, Hemker HC. Fibrin-dependent platelet procoagulant activity requires GP1b receptors and von Willebrand factor. Blood 1999; 93: Langdell RD, Wagner RH, Brinkhous KM. Effect of anti-hemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage anti-hemophilia assay procedure. J Lab Clin Med 1953; 41: Biggs R, MacFarlane RG. The reaction of haemophilic plasma to thromboplastin. J Clin Path 1951; 4: Hartert H. Thrombelastography, a method for physical analysis of blood coagulation. Z Gesamte Exp Med 1951; 117: AlDieri R, Peyvandi F, Santagostino E et al. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding. Thromb Haemost 2002; 88: Haemophilia (2006), 12, (Suppl. 3), Journal compilation Ó 2006 Blackwell Publishing Ltd
6 NEW APPROACHES FOR MEASURING COAGULATION Hemker HC, Giesen P, AlDieri R et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32: Hemker HC, Beguin S. Phenotyping the clotting system. Thromb Haemost 2000; 84: Dargaud Y, Beguin S, Lienhart A et al. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B. Thromb Haemost 2005; 93: McIntosh JH, Owens D, Lee CA, Raut S, Barrowcliffe TW. A modified thrombin generation test for the measurement of factor VIII concentrates. J Thromb Haemost 2003; 1: Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 2003; 1: Ingerslev J, Poulsen LH, Sørensen B. Potential role of the dynamic properties of whole blood coagulation in assessment of dosage requirements in haemophilia. Haemophilia 2003; 9: Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Identifying hypocoagulable states with a modified global assay of overall haemostasis potential in plasma. Blood Coagul Fibrinolysis 2005; 16: Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 2005; 3: Journal compilation Ó 2006 Blackwell Publishing Ltd Haemophilia (2006), 12, (Suppl. 3), 76 81
LABORATORY APPROCH TO THE BLEEDING PATIENT
Anne Winkler, MD Emory University School of Medicine, Atlanta Georgia Assistant Professor, Pathology & Laboratory Medicine Medical Director, Transfusion Service, Grady Health System Assistant Director,
More informationLABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY
LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY 1 WHEN IS THE LAB REQUIRED TO INVESTIGATE FOR A POSSIBLE BLEEDING DISORDER? Clinically suspected bleeding tendency
More informationHow to Approach a Patient with Bleeding. Nigel Key MB ChB FRCP. November 1, ISTH Advanced Training Course. ISTH Advanced Training Course
How to Approach a Patient with Bleeding Nigel Key MB ChB FRCP November 1, 2016 Disclosures for Nigel Key In compliance with COI policy, ISTH requires the following disclosures to the session audience:
More informationThe Calibrated Automated Thrombogram (CAT): a universal routine test for hyperand hypocoagulability
Pathophysiol Haemost Thromb, 2002;32:249-253 The Calibrated Automated Thrombogram (CAT): a universal routine test for hyperand hypocoagulability H.C. Hemker 1 ; P.Giesen 1, R. AlDieri 1, V. Regnault 2,
More informationCurrent laboratory practices in the diagnosis and management of haemophilia
Current laboratory practices in the diagnosis and management of haemophilia Marc Jacquemin University of Leuven BSTH 2013 Detection of severe haemophilia A Validation of the FVIII assay for the detection
More informationIntroduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO
Introduction Hemostasis: Tourniquet Test & Bleeding Time Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO Hemostasis A series of reactions that function to stop bleeding, maintaining
More informationThe Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors
Venkat Living Venkat with Hemophilia Living with Hemophilia The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors Tami Livnat 1, Alfica
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationCharacterization of IGIV Products by Tests. Indicative for the Thromboembolic Potential
Characterization of IGIV Products by Tests Indicative for the Thromboembolic Potential Plasma Product Biotechnology Meeting, Cyprus Wolfgang Teschner, Ursula Mais-Paul, Brigitte Talir and Hans-Peter Schwarz
More informationGeneral Principles of. Hemostasis. Kristine Krafts, M.D.
General Principles of Hemostasis Kristine Krafts, M.D. Hemostasis is a balancing act! pro-ting plugs up holes in blood vessels anti-ting keeps ting under control Pro-Clotting Pro-Clotting vessels platelets
More informationClot waveform analysis: Where do we stand in 2017?
Received: 28 April 2017 Accepted: 11 July 2017 DOI: 10.1111/ijlh.12724 REVIEW Clot waveform analysis: Where do we stand in 2017? P. O. Sevenet F. Depasse Diagnostica Stago S.A.S, Asnières sur Seine, France
More informationEmergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information. Wayne Chandler, MD Laboratory Medicine Seattle Children s
Emergency and Perioperative Hemostasis Testing: Which Assays Provide Helpful Information Wayne Chandler, MD Laboratory Medicine Seattle Children s Emergency Hemostasis Testing Patients actively bleeding
More informationEvaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues
Evaluation of Complex Coagulation Cases: Case-Based Illustrations of Important Issues Kristi J. Smock, MD Associate Professor of Pathology University of Utah Health Sciences Center Medical Director, Hemostasis/Thrombosis
More informationCoagulation Mechanisms Dr. Nervana Bayoumy
Coagulation Mechanisms Dr. Nervana Bayoumy Associate Professor Department of Physiology Objectives At the end of this lecture you should be able to: 1. Recognize the different clotting factors 2. Understand
More informationCitation for published version (APA): Bakhtiari, K. (2013). Laboratory investigation in normal and pathologic coagulation.
UvA-DARE (Digital Academic Repository) Laboratory investigation in normal and pathologic coagulation Bakhtiari, K. Link to publication Citation for published version (APA): Bakhtiari, K. (2013). Laboratory
More informationCoagulation in perspective: Blood management. Objectives
Coagulation in perspective: Blood management Julie Wegner, PhD jawrbl@gmail.com Objectives To gain a basic understanding of the following: 1. Coagulation components and processes Why patients bleed. 2.
More informationThese handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides. If you would like the 1 slide per page handouts, please ask
More informationPrimary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system
Primary hemostasis Vascular endothelium Vasoconstriction : local tissue factor, nervous system Platelet Plug Platelet Adhesion Platelet Activation Platelet Aggregation Platelet Plug Formation Secondary
More informationThrombin generation assays: accruing clinical relevance H. Coenraad Hemker, Raed Al Dieri and Suzette Béguin
Thrombin generation assays: accruing clinical relevance H. Coenraad Hemker, Raed Al Dieri and Suzette Béguin Purpose of review After decades of near oblivion, thrombin generation is being revived as an
More informationLocal vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors
Hemostasis Hemostasis ( hemo =blood; sta= remain ) is the stoppage of bleeding, which is vitally important when blood vessels are damaged. Following an injury to blood vessels several actions may help
More informationFactor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs
Factor Concentrates. More is better? Alexander Duncan MD Emory Medical Labs Call from OR! Scenario -1 Patients is bleeding out! Don t ask why, what rate what s been done! We need blood now! What kind of
More informationPrincess Alexandra Hospital Emergency Department. Clinical Procedure. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationLaboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016
Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016 Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be
More informationSuitability of analytical methods for detection of thrombogenic factor XIa in Privigen
Suitability of analytical methods for detection of thrombogenic factor XIa in Privigen Absence of thrombogenic factors in Privigen M. Moses, K. Ruhwedel, H.-A. Stöhr, L. Duse, A. Feussner, W. Wormsbächer,
More informationHaemostasis Reagents product list 2018
Milan Analytica AG Baslerstrasse 15 4310 Rheinfelden www.milananalytica.ch Product # ** = Smaller Kit Format specifically designed for Helena C-1/2/4/AC-4 ^ = For use with Helena C-1/2/4/AC-4 Product name
More informationClinical Procedure. ROTEM Trauma, Resuscitation. Princess Alexandra Hospital Emergency Department. 1 Introduction
Princess Alexandra Hospital Emergency Department Clinical Procedure Trauma, Resuscitation Review Officer: Glenn Ryan 1 Introduction Version no: 1 Approval Date: 16/07/2014 Review Date: 16/07/2016 Authority:
More informationSysmex Educational Enhancement & Development
Sysmex Educational Enhancement & Development SEED-Africa Newsletter No 9 2011 Quality control in coagulation testing Basic Coagulation The purpose of this newsletter is to provide an overview of internal
More informationCommon Inherited Bleeding Disorders
CAA 2015 Annual Conference Common Inherited Bleeding Disorders Bob Miller, A October 8, 2015 VWF has two jobs Loosely bound to protect FVIII and tether to site of injury All other coagulation factors also
More informationMeasurement of Thrombin Generation in Conditions of Low Antithrombin
Measurement of Thrombin Generation in Conditions of Low Antithrombin Peter L.A. Giesen, Henri M.H. Spronk, Rene van Oerle, Alfica Sehgal, Akin Akinc 11 July 217 ISTH Berlin, Germany 1 Measuring Thrombin
More informationSysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc All rights reserved.
Excel with Confidence Sysmex CS-2500 Hemostasis System Unrestricted Siemens Healthcare Diagnostics Inc. 2015 All rights reserved. General Lab Challenges Test Volume Financial Performance Accuracy Reliability
More informationEVOLUTION OF INHIBITOR TREATMENT
EVOLUTION OF INHIBITOR TREATMENT Flora Peyvandi Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico and University of Milan, Italy February
More informationTransfusion & Non-transfusion Approaches to Bleeding
Transfusion & Non-transfusion Approaches to Bleeding Maureane Hoffman, MD, PhD Professor of Pathology, Duke University and Director, Transfusion Service and Hematology Laboratory Durham Veterans Affairs
More informationSign up to receive ATOTW weekly -
BLOOD PHYSIOLOGY PART 2 ANAESTHESIA TUTORIAL OF THE WEEK 231 11 TH JULY 2011 Dr Karen Hayes Royal Devon & Exeter Correspondence to: kmhayes@hotmail.co.uk QUESTIONS Before continuing, try to answer the
More informationUsing TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS
Using TEG in the ED, OR, and ICU Don H. Van Boerum, MD, FACS Trauma Surgeon, Director of Surgical Critical Care, Co-Director of Shock Trauma ICU, Intermountain Medical Center, Intermountain Healthcare
More informationPROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)
PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY) PROTHROMBIN TIME DEFINITION The Prothrombin time is the functional determination of the extrinsic coagulation pathway. It is a widely used laboratory
More informationThe Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli
The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management Elham Khalaf Adeli Overview PBM, bleeding management, Coagulation POC Testing Review of laboratory conventional coagulation
More informationThe Coagulation Workup In The Office Setting
CAA Conference alm Springs 2012 The Coagulation Workup In The Office Setting CAA Conference alm Springs, October 2012 Robert Miller, A-C Henoch-Schoenlein urpura 1 CAA Conference alm Springs 2012 2 CAA
More informationPlasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.
Test Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems. Karen A. Moffat BEd, MSc, ART, FCSMLS(D) Technical Specialist, Coagulation, HRLMP Assistant Professor, Department of
More informationUse of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients
CM&R Rapid Release. Published online ahead of print July 22, 2009 as Use of Chromogenic Assay of Factor X to Accept or Reject INR Results in Warfarin Treated Patients Michael J. Sanfelippo, MS, MT ASCP;
More informationSysmex Educational Enhancement and Development No
SEED Coagulation Sysmex Educational Enhancement and Development No 1 2016 Assessing platelet function a basic introduction The purpose of this newsletter is to provide a basic overview of platelet function
More informationOVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS
OVERVIEW OF LABORATORY DIAGNOSTIC TESTING FOR PLATELET DISORDERS Catherine P. M. Hayward, MD PhD, FRCP(C) Head, Coagulation, Hamilton Regional Laboratory Medicine Program Professor, Pathology and Molecular
More informationCoagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1
Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1 Donna D. Castellone, MS, MT (ASCP) SH Clinical Project Manager Hematology and Hemostasis Siemens Healthcare Diagnostics Disclosures
More informationCritical aspects in routine coagulation testing
Pure & Appl. Chem., Vol. 68, No. 10, pp. 1867-1871,1996, Printed in Great Britain. 0 1996 IUPAC Critical aspects in routine coagulation testing A. D'Angelo, P. Della Valle, L. Crippa, E. Pattarini, S.
More informationPearls and Pitfalls in Factor Inhibitor Testing
Pearls and Pitfalls in Factor Inhibitor Testing Dorothy M. Adcock M.D. Esoterix Coagulation, Laboratory Corporation of America Holdings ISLH May 19, 2015 Outline Overview of coagulation factor inhibitors
More information378 Biomed Environ Sci, 2014; 27(5):
378 Biomed Environ Sci, 2014; 27(5): 378-384 Original Article Thrombin Generation Increasing with Age and Decreasing with Use of Heparin Indicated by Calibrated Automated Thrombogram Conducted in Chinese
More informationClinical Policy: Humate-P (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404
Clinical Policy: (Antihemophiliac Factor/von Willebrand Factor Complex Human) Reference Number: CP.MP.404 Effective Date: January 2008 Last Review Date: 12/16 See Important Reminder at the end of this
More informationHemostasis practice: state-of-the-art
Perspective Page 1 of 6 Hemostasis practice: state-of-the-art Giuseppe Lippi 1, Emmanuel J. Favaloro 2 1 Section of Clinical Biochemistry, Department of Neurological, Biomedical and Movement Sciences,
More informationCommon Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)
Common Inherited Coagulation Disorders Bob Miller, A 2017 Inherited Coagulation Disorders Brief review of coagulation Disorders related to platelet dysfunction (not the acquired thrombocytopenias) Disorders
More informationAdv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:
Adv Pathophysiology Unit 4 Page 1 of 10 Learning Objectives for this file: Topics include structure & function of: 1. Coagulation process platelets, clotting factors 2. Coagulation cascade formation of
More informationR.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,
Institut J. Bordet Normal with Actin-FS avoids intrinsic pathway factors assays in the presence of an isolated prolongation of (Platelin-LS) without hemorrhagic history R.Li, C.Swaelens, F.Vandermijnsbrugge,
More informationDEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK
DEPARTMENT OF CLINICAL LABORATORY SCIENCES SCHOOL OF HEALTH TECHNOLOGY AND MANAGEMENT THE UNIVERSITY AT STONY BROOK STONY BROOK, NEW YORK 11794-8205 COAGULATION COMPETENCY EVALUATION FORM STUDENT NAME:
More informationHaemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis
Haemostasis Haemostasis The function of haemostasis is: to prevent blood loss from injured vessels to stop bleeding to prevent thrombosis Haemostasis blood endothelium basement membrane subendothelium
More informationLaboratory Monitoring of Anticoagulation
Michael Smith, Pharm. D., BCPS, CACP East Region Pharmacy Clinical Manager Hartford HealthCare Learning Objectives Explain the role of common laboratory tests used in monitoring of anticoagulation therapy.
More informationDr. Susan Louw Haematopathologist NHLS / WITS / SASTH
Dr. Susan Louw Haematopathologist NHLS / WITS / SASTH Since 1948 Initially a research tool Utility in management of bleeding and thrombosis Guide clotting factor replacement, platelet / blood transfusions
More informationActivated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?
Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective? Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia
More informationClumsy Coagulation Communication
Clumsy Coagulation Communication Let s Blame the Lab! Lab Clinician Communication Barriers and opportunities Where are the errors made? How do we enhance patient experience? George A Fritsma MS, MLS, Your
More informationSAMPLE. Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay
2nd Edition H48 Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay This guideline provides recommendations regarding the proper collection and handling of specimens, reagents,
More informationCoagulopathy Case-2. Andy Nguyen, M.D. 2009
Coagulopathy Case-2 Andy Nguyen, M.D. 2009 CLINICAL HISTORY A 42 year-old man brought to the emergency room with severe burn. Patient was rescued by firemen in a serious fire. He had been found unconscious
More informationLinking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity
Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity Abhishek Gulati What is enoxaparin? Low molecular weight heparin anticoagulant Used to minimise the
More informationUse of ROTEM from the Laboratory Perspective. A/Prof David Roxby SA Pathology
Use of ROTEM from the Laboratory Perspective A/Prof David Roxby SA Pathology What s the Problem? Constant changes in treatment recommendations Lack of good evidence to guide practice Variations in clinical
More informationLABORATORY DIAGNOSIS OF BLEEDING DISORDERS
LABORATORY DIAGNOSIS OF BLEEDING DISORDERS Primary & Secondary Hemostasis Disorders http://.columbia.edu/itc/hs/medical/selective/advclinicalpathology/2004/lecture/lab%20diagnosis%20of%20bleeding%20disorders.ppt
More informationVenous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? New Chest Guidelines 2016
Venous thromboembolism (VTE) Can Biomarkers Help to Guide Duration of Therapy After VTE? Marlene Grenon, MD Associate Professor of Surgery University of California San Francisco UCSF Vascular Surgery Symposium
More informationHematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม
Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม Hematotoxin producing snakes Pit vipers (Crotalinae) Malayan pit viper (Calloselasma rhodostoma) Green pit viper (Trimeresurus
More informationDisclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim
Test Disclosures I have received research funding from: Novo Nordisk CSL-Behring Boehringer Ingelheim I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Baxter The Medicines Company
More informationCoagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.
Coagulation Cascade Intrinsic Pathway Extrinsic Pathway Contact Activation XIIa XI XIa Prekallikrein HMW Kininogen IX IXa Ca 2+ Anticoagulation proteins: Protein C, Protein S, Antithrombin III, TFPI TF
More informationHemostasis and Thrombosis
Hemostasis Hemostasis and Thrombosis Normal hemostasis is a consequence of tightly regulated processes that maintain blood in a fluid state in normal vessels, yet also permit the rapid formation of a hemostatic
More informationAT Reduction Corrects Thrombin Generation in Samples From Hemophilia A & B Patients With Inhibitors
AT Reduction Corrects Thrombin Generation in Samples From Hemophilia A & B Patients With Inhibitors Gili Kenet, Tami Livnat, Emma Fosbury, Pratima Chowdary, Alfica Sehgal, Akin Akinc, Benny Sorensen 1
More informationInternational Society Laboratory Hematology Milan, May Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016
International Society Laboratory Hematology Milan, 12-14 May 2016 Current and Emerging Approaches for Assessing von Willebrand disease (VWD) in 2016 Augusto B. FEDERICI Hematology and Transfusion Medicine
More informationDevelopment of a Novel Automated Screening Method for Detection of FVIII Inhibitors
Development of a Novel Automated Screening Method for Detection of FVIII Inhibitors Matthew S. Evans, MD Assistant Professor of Hematology and Pathology Department of Hematology Hemophilia Treatment Center
More informationLaboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation
Laboratory Investigation of Challenging Cases Laura A. Worfolk, Ph.D Scientific Director, Coagulation Coagulation Cascade XII XIIa XI HMWK/Prekallikrein XIa VII Injury IX X IXa VIII Xa X TF TF/VIIa Prothrombin
More informationA SIMPLE METHOD OF STUDYING THE GENERATION OF THROMBIN IN RECALCIFIED PLASMA
J. clin. Path. (1953), 6, 9. A SIMPLE METHOD OF STUDYING THE GENERATION OF THROMBIN IN RECALCIFIED PLASMA APPLICATION IN THE INVESTIGATION OF HAEMOPHILIA BY W. R. PITNEY AND J. V. DACIE From the Department
More informationWhy measure thrombin generation? How does measurement of thrombin generation work? Sample material / pre-analytics Test performance Applications
Why measure thrombin generation? How does measurement of thrombin generation work? Sample material / pre-analytics Test performance Applications Revision V02/2009 Theory of coagulation, 1905 thromboplastin
More informationXXI st Congress of the International Society on Thrombosis and Haemostasis
2 XXI st Congress of the International Society on Thrombosis and Haemostasis Congress aemostasis hrombosis news 2(2 st ISTH),,7 6 ( )2 ( )74 78,, ISTH 2,9742,,,,,,,, Report FVIII-specific memory B-cells
More informationApheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017
Apheresis Anticoagulant Removal Oluwatoyosi Onwuemene, MD MS May 6th, 2017 Talk Outline Case presentation Factors associated with drug removal TPE s effects on hematologic parameters Anticoagulant properties
More informationHemostasis. by Mohie-Aldien Elsayed
Hemostasis by Mohie-Aldien Elsayed Hemostasis Hemostasis is defined as the process that maintains the flowing blood in a fluid state and confined to the circulatory system Coagulation prevents excess blood
More informationBLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.
BLOOD COAGULATION The ability of the body to control the flow of blood following vascular injury is paramount to continued survival. The process of blood clotting and then the subsequent dissolution of
More informationNEW INITIATIVES. Factor XIII, Fibrinolysis, Heparin. Piet Meijer. ECAT Foundation. Leiden The Netherlands
NEW INITIATIVES Factor XIII, Fibrinolysis, Heparin Piet Meijer ECAT Foundation Leiden The Netherlands DISCLOSURE Relevant Financial Relationship(s) None Off Label Usage None Pilot study on Fibrinolytic
More informationStago Newsletter. Volume 6 Issue 1 May 2016
1 Stago Newsletter Volume 6 Issue 1 May 2016 Haemostasis Catalogue 2016 2 INSIDE THIS ISSUE: 2016 Haemostasis Catalogue 2 VWF Collagen Binding 3 Customer Corner 4 ihemostasis and Haemoscore 5 Continuing
More informationAbdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018
Personalized hemophilia treatment Abdulkareem Almomen, MD, FRCPC, Professor of Medicine-Hematology, King Saud University & Blood and Cancer Center, Riyadh Jeddah, 24 February 2018 Evolution of Hemophilia
More informationAcute Traumatic Coagulopathy
Jean-Francois Pittet, M.D. Depts of Anesthesia and Surgery Cardiovascular Research Institute University of California San Francisco Acute Traumatic Coagulopathy Plan 1. Description of the coagulation system
More informationFactor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate
Factor VIII Concentrate Factor IX Complex (Coagulation Factors, II, VII, IX, X) Concentrate Application for retention on the WHO Model List From: Plasma Protein Therapeutics Association (PPTA) 1. Summary
More informationPrior Authorization Criteria Hemophilia/Blood Factor Products
Prior Authorization Criteria Hemophilia/Blood Factor Products All requests for Hemophilia/Blood Factor Products require a prior authorization and will be screened for medical necessity and appropriateness
More informationQuality Assurance and Quality Control of Thromboelastography and Rotational Thromboelastometry: The UK NEQAS for Blood Coagulation Experience
Quality Assurance and Quality Control of Thromboelastography and Rotational Thromboelastometry: The UK NEQAS for Blood Coagulation Experience Dianne P. Kitchen, F.I.B.M.S., 1 Steve Kitchen, Ph.D., 1 Ian
More informationLaboratory Aspects of recombinant porcine FVIII and extended half life concentrates
Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates Rajiv K. Pruthi, M.B.B.S Co-Director, Special Coagulation Laboratory & Director, Mayo Comprehensive Hemophilia Center
More informationCoagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117
www.cap.org Coagulation Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Serviced (CMS). Coagulation Limited CGL, CGDF Analyte CGL CGDF New
More informationChanges in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase
Clinical Hemorheology and Microcirculation 23 (2000) 213 218 213 IOS Press Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase Lirong Jin
More informationTable of Contents. Introduction. Worldwide Market and Technology Overview
Table of Contents Introduction Worldwide Market and Technology Overview A. Major Routine and Special Coagulation Tests 1. Introduction 2. Activated Partial Thromboplastin Time (APTT) 3. Alpha-2 Antiplasmin
More informationThe Role of Disease Foundations in Moving Gene Transfer Forward
The Role of Disease Foundations in Moving Gene Transfer Forward Mark W. Skinner WFH President 7 April 2005 ASGT Stakeholder Meeting WFH Mission Introduce Improve Maintain Care for people with hemophilia
More informationMechanisms and monitoring of bypassing agent therapy
Journal of Thrombosis and Haemostasis, 10: 1478 1485 DOI: 10.1111/j.1538-7836.2012.04793.x REVIEW ARTICLE Mechanisms and monitoring of bypassing agent therapy M. HOFFMAN* and Y. DARGAUD *Duke University,
More informationEvaluation of the Bleeding Patient
Evaluation of the Bleeding Patient Screening Tests Rong He, MD Special Coagulation Laboratory, Division of Hematopathology 2015 MFMER slide-1 DISCLOSURE Relevant Financial Relationship(s) None 2015 MFMER
More informationPotentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition
Potentiation of Thrombin Generation in Hemophilia A Plasma by Coagulation Factor VIII and Characterization of Antibody-Specific Inhibition Bhavya S. Doshi 1, Bagirath Gangadharan 2, Christopher B. Doering
More informationLe indicazioni cliniche per l utilizzo dei fattori della coagulazione
Le indicazioni cliniche per l utilizzo dei fattori della coagulazione Elena Santagostino Centro Emofilia e Trombosi A. Bianchi Bonomi Fondazione Ca Granda, Ospedale Maggiore di Milano L'utilizzo dei medicinali
More informationActivated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin Monitoring. Biochemical Basis for Discordance
Coagulation and Transfusion Medicine / vs Level Discrepancies ctivated Partial Thromboplastin Time and Measurements in Heparin Monitoring iochemical asis for Discordance Clifford M. Takemoto, MD, 1 Michael.
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE
More informationMonitoring thrombin generation: Is addition of corn trypsin inhibitor needed?
2009 Schattauer GmbH, Stuttgart New Technologies, Diagnostic Tools and Drugs Monitoring thrombin generation: Is addition of corn trypsin inhibitor needed? Henri M. H. Spronk 1 ; Arne W. J. H. Dielis 1
More informationAlternative Haemostatic Agents in the Management of Obstetric Haemorrhage
Alternative Haemostatic Agents in the Management of Obstetric Haemorrhage Clinical Associate Professor Nolan McDonnell School of Medicine and Pharmacology, School of Women s and Infants Health University
More informationDiagnosing Haemostasis PRODUCT CATALOG
Diagnosing Haemostasis PRODUCT CATALOG CONTENTS MTI COAGULATION ANALYZER MT1C- Single Channel Semi Automated Coagulation Analyzer MT4C- Four Channel Semi Automated Coagulation Analyzer Bera - New Generation
More information2 Thomas G. DeLoughery
Tests of Hemostasis and Thrombosis 2 Thomas G. DeLoughery A routine laboratory test once well-established is often slavishly adhered to, with little further thought about how it originated, why it is done
More informationBasic coagulation applications and case studies
Basic coagulation applications and case studies Jing Jin Clinical laboratory Scientist (MLS, ASCP) - Coagulation/Hematology Stanford University Hospital and Clinics 1 Agenda Overview about 3 major phases
More informationUK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione
UK NEQAS FOR BLOOD COAGULATION: Programmi EQAS nel laboratorio di coagulazione Tim Woods, Manager UK NEQAS for Blood Coagulation STH Royal Hallamshire Hospital Sheffield U.K. www.ukneqasbc.org Quality
More information